Table 4.

Genes/SNPs associated with cHL prognosis, treatment-related secondary malignancies and toxicities

GenesSNPAllele comparisonTreatmentAssociationsReference
UGT1A1TA repeatTA6/6 vs. TA6/7/TA7/7ABVD/ChIVPP (70%), BEACOPP (11%), CHOP/COP/CHOEP (19%) + RTAdverse OS(69)
TA repeatTA6/6 vs. TA6/7/TA7/7ABVD (66%), EBVP (22%), BEACOPP (12%)Adverse FFP/OS/FFTF(68)
TRBPrs784567TT/TC vs. CCABVD (52%), MOPPABVD (38%)Adverse DFS(71)
XPO5rs11077AA/CC vs. ACABVD (52%), MOPPABVD (38%)Adverse DFS(71)
PRDM1rs4946728A vs. CRT/CHT (55%), RT only (41%), NA (4%)Risk of any malignancy(48)
rs1040411G vs. ART/CHT (55%), RT only (41%), NA (4%)Risk of any malignancy(48)
GSTM1DeletionDeletion vs. presentRT/CHT (63%), RT only (37%)Risk of any malignancy/cancer within radiation field(72)
KRT81rs3660CC vs. GGABVD (52%), MOPPABVD (38%)Risk of neurologic toxicity(71)
XPO5rs11077AC vs. AA/CCABVD (52%), MOPPABVD (38%)Risk of pulmonary toxicity(71)

Abbreviations: BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisolone, procarbazine; C(H)O(E)P: cyclophosphamide, (doxorubicin), vincristine, (etoposide), prednisolone; ChIVPP: chlorambucil, vinblastine, prednisolone, procarbazine; CHT, chemotherapy; DFS, disease-free survival; FFP, free from progression; FFS, failure-free survival; FFTF, freedom from treatment failure; MOPP, mustargen, oncovin, procarbazine, prednisone; NA, not available; OS, overall survival; RT, radiotherapy.